Clearmind Trial Gets Unanimous Approval After Safety Review
Topline from the first dosing cohort: no serious adverse events, generally good tolerability, and strong protocol adherence. An independent...
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule
Climb Bio granted a non-statutory option covering 120,000 shares at an exercise price of $1.76 to a single new...
NCCN Adds Ziftomenib to Acute Myeloid Leukemia Guidelines
Komet-001 reported a 21.4% CR/CRh rate with a median duration of response of five months in adults with relapsed...
BioMX Provides Important Update on BX004 CF Phase 2b Trial
An independent data monitoring committee for BiomX’s Phase 2b BX004 trial in cystic fibrosis recommended the study continue with...
CG Oncology to Present Cretostimogene Results at SUO Meeting
No efficacy or safety figures were disclosed ahead of the meeting. CG Oncology signaled that topline data from the...
Profound Medical Unveils AI BPH Module, New Clinical Data
Perioperative data from the CAPTAIN randomized trial indicated lower blood loss, shorter length of stay, reduced post‑operative pain, and...
First Patient Dosed in Innocare’s Prurigo Nodularis Trial
InnoCare has dosed the first patient in a global Phase II trial of its oral TYK2 inhibitor, soficitinib (ICP-332),...
Silexion Completes SIL204 Toxicology for Pancreatic Cancer
Two-species toxicology for Silexion’s siRNA candidate SIL204 reported no systemic organ toxicity, clearing a key preclinical gate and keeping...
Tempest Closes Up To $8.35M Registered Direct Offering
Tempest Therapeutics closed a registered direct offering of 1,172,414 shares at $3.625 per share for approximately $4.25 million in...
Hutchmed Highlights Data for ESMO Asia, ASH 2025 Meetings
No efficacy or safety figures were disclosed ahead of the meetings, but HUTCHMED will take a broad slate of...